Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 4
1(20.0%)
5Total
N/A(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT02201134Not ApplicableCompleted

SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia

Role: collaborator

NCT02907554Phase 4Completed

Cyclosporine a Pretreatment and Kidney Graft Function

Role: collaborator

NCT02150018Unknown

Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography

Role: collaborator

NCT02510105Not ApplicableUnknown

Tomodensitometric Study of Pulmonary Effects of Intrapulmonary Percussive Ventilation in ARDS Patients

Role: collaborator

NCT02361021Unknown

Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound

Role: collaborator

NCT02367339Unknown

Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff

Role: collaborator

NCT01906203Not ApplicableCompleted

Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance

Role: collaborator

NCT01196754Not ApplicableCompleted

Pharmacokinetic of Sevoflurane During a 48h Sedation in Intensive Care Unit With AnaConDa®

Role: collaborator

All 8 trials loaded